title: [Micafungin for the treatment of neonatal invasive candidiasis].
abstract: BACKGROUND
  In neonatal intensive care units, deep fungal disease due to Candida spp. are an important clinical problem, partly due to the increasing prevalence of Candida disease and also to the high associated and constant morbimortality; both factors are independently maintained though there has been a significant improvement in the management of neonatal patients.
  
  
  OBJECTIVE
  To define the therapeutic use of micafungin for the treatment of neonatal invasive candidiasis.
  
  
  METHODS
  We use a review of biomedic data bases namely Medline and EMBASE.
  
  
  CONCLUSIONS
  Micafungin is the latest introduced echinocandin. It has a wide spectrum of activity and covers Candida albicans and non-albicans Candida species. It has scarce drugs interactions and is devoid of toxicity, being an attractive approach for the treatment of invasive candidiasis (without meningitis, endocarditis and endophthalmitis). Althought the European Medicines Agency approved in 2008 the use of Micafungin for the treatment of invasive candidiasis in children, the available clinical experience is limited and currently more clinical studies are warranted to define its efficacy and safety in neonates.
authors.affiliation: Servicio de Neonatología, Hospital Universitario 12 de Octubre, Madrid, España. eleninf@hotmail.com
authors.forename: María Elena
authors.initials: ME
authors.lastname: Infante-López
authors.forename: Pablo
authors.initials: P
authors.lastname: Rojo-Conejo
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D016469:Fungemia / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000382:microbiology; D055666:Lipopeptides / Q000627:therapeutic use*; D008297:Male; D015201:Meta-Analysis as Topic; D000077551:Micafungin; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012189:Retrospective Studies
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077551:Micafungin